ArticleCancers2022

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.

Paweł Rogala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.